Patrick J Mcgrath

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1061379/publications.pdf

Version: 2024-02-01

171 papers	24,642 citations	23567 58 h-index	7745 150 g-index
175 all docs	175 docs citations	175 times ranked	22609 citing authors

#	Article	IF	Citations
1	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1905-1917.	7.2	4,241
2	Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice. American Journal of Psychiatry, 2006, 163, 28-40.	7.2	3,206
3	Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature Genetics, 2018, 50, 668-681.	21.4	2,224
4	Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics, 2013, 45, 984-994.	21.4	2,067
5	A mega-analysis of genome-wide association studies for major depressive disorder. Molecular Psychiatry, 2013, 18, 497-511.	7.9	1,002
6	Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Contemporary Clinical Trials, 2004, 25, 119-142.	1.9	898
7	Harmonization of cortical thickness measurements across scanners and sites. NeuroImage, 2018, 167, 104-120.	4.2	790
8	A Comparison of Lithium and T₃Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1519-1530.	7.2	526
9	Regional brain asymmetries in major depression with or without an anxiety disorder: A quantitative electroencephalographic study. Biological Psychiatry, 1997, 41, 939-948.	1.3	305
10	Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1531-1541.	7.2	300
11	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. American Journal of Psychiatry, 2007, 164, 739-752.	7.2	297
12	A Genomewide Association Study of Citalopram Response in Major Depressive Disorder. Biological Psychiatry, 2010, 67, 133-138.	1.3	289
13	Electroencephalographic Alpha Measures Predict Therapeutic Response to a Selective Serotonin Reuptake Inhibitor Antidepressant: Pre- and Post-Treatment Findings. Biological Psychiatry, 2008, 63, 1171-1177.	1.3	244
14	Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Molecular Psychiatry, 2011, 16, 202-215.	7.9	239
15	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1161-1172.	7.2	233
16	Antidepressants Normalize the Default Mode Network in Patients With Dysthymia. JAMA Psychiatry, 2013, 70, 373.	11.0	231
17	Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. Journal of Psychiatric Research, 2016, 78, 11-23.	3.1	216
18	Imipramine Treatment of Alcoholics With Primary Depression. Archives of General Psychiatry, 1996, 53, 232.	12.3	212

#	Article	IF	Citations
19	Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D Report. American Journal of Psychiatry, 2009, 166, 599-607.	7.2	209
20	Sequence Analysis of the Serotonin Transporter and Associations with Antidepressant Response. Biological Psychiatry, 2005, 58, 374-381.	1.3	203
21	Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant21Data from two treatment protocols were combined so as to yield sufficient samples of female and male fluoxetine responders and nonresponders. With the exception of the initial placebo period in one study, the treatment protocols were comparable in terms of both fluoxetine doses and the raters evaluating treatment response. Most importantly, the differences between fluoxetine responder. Biological Psychiatry, 2001, 49, 416-425.	1.3	200
22	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1161.	7.2	167
23	Imipramine Treatment of Opiate-Dependent Patients With Depressive Disorders. Archives of General Psychiatry, 1998, 55, 153.	12.3	158
24	Columbia Atypical Depression. British Journal of Psychiatry, 1993, 163, 30-34.	2.8	157
25	An electroencephalographic signature predicts antidepressant response in major depression. Nature Biotechnology, 2020, 38, 439-447.	17.5	157
26	Childhood trauma history is linked to abnormal brain connectivity in major depression. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8582-8590.	7.1	151
27	Analysis of Association Between the Serotonin Transporter and Antidepressant Response in a Large Clinical Sample. Biological Psychiatry, 2007, 61, 734-742.	1.3	148
28	Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample. PLoS ONE, 2008, 3, e1872.	2.5	144
29	Current Source Density Measures of Electroencephalographic Alpha Predict Antidepressant Treatment Response. Biological Psychiatry, 2011, 70, 388-394.	1.3	132
30	Atypical Depression: A Valid Clinical Entity?. Psychiatric Clinics of North America, 1993, 16, 479-495.	1.3	128
31	Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression. JAMA Psychiatry, 2018, 75, 547.	11.0	125
32	Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome. Drug and Alcohol Dependence, 2009, 99, 248-260.	3.2	124
33	Are There Differences Between Womenâ€™s and Menâ€™s Antidepressant Responses?. American Journal of Psychiatry, 2002, 159, 1848-1854.	7.2	123
34	Right brain, left brain in depressive disorders: Clinical and theoretical implications of behavioral, electrophysiological and neuroimaging findings. Neuroscience and Biobehavioral Reviews, 2017, 78, 178-191.	6.1	122
35	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. Biological Psychiatry, 2022, 91, 313-327.	1.3	114
36	Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study. Psychological Medicine, 2019, 49, 1118-1127.	4.5	109

#	Article	IF	Citations
37	Psychomotor Slowing as a Predictor of Fluoxetine Nonresponse in Depressed Outpatients. American Journal of Psychiatry, 2006, 163, 73-78.	7.2	100
38	Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug and Alcohol Dependence, 1995, 39, 185-195.	3.2	99
39	Predictors of Relapse in a Prospective Study of Fluoxetine Treatment of Major Depression. American Journal of Psychiatry, 2006, 163, 1542-1548.	7.2	95
40	Placebo-Controlled Trial of Dehydroepiandrosterone (DHEA) for Treatment of Nonmajor Depression in Patients With HIV/AIDS. American Journal of Psychiatry, 2006, 163, 59-66.	7.2	95
41	Primary Versus Specialty Care Outcomes for Depressed Outpatients Managed with Measurement-Based Care: Results from STAR*D. Journal of General Internal Medicine, 2008, 23, 551-560.	2.6	92
42	When Should a Trial of Fluoxetine for Major Depression Be Declared Failed?. American Journal of Psychiatry, 2003, 160, 734-740.	7.2	91
43	Response to a Selective Serotonin Reuptake Inhibitor (Citalopram) in Major Depressive Disorder With Melancholic Features. Journal of Clinical Psychiatry, 2008, 69, 1847-1855.	2.2	91
44	Use of Pattern Analysis to Predict Differential Relapse of Remitted Patients With Major Depression During 1 Year of Treatment With Fluoxetine or Placebo. Archives of General Psychiatry, 1998, 55, 334-43.	12.3	90
45	Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. American Journal of Psychiatry, 2015, 172, 881-891.	7.2	87
46	Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study. Neuropsychopharmacology, 2016, 41, 454-463.	5.4	84
47	Substance Use Disorder Comorbidity in Major Depressive Disorder: A Confirmatory Analysis of the STAR*D Cohort. American Journal on Addictions, 2006, 15, 278-285.	1.4	83
48	Reduced brain responses to novel sounds in depression: P3 findings in a novelty oddball task. Psychiatry Research, 2009, 170, 218-223.	3.3	82
49	Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenetics and Genomics, 2009, 19, 1-10.	1.5	81
50	Brain ERPs of depressed patients to complex tones in an oddball task: Relation of reduced P3 asymmetry to physical anhedonia. Psychophysiology, 1998, 35, 54-63.	2.4	80
51	Adverse Reactions to Monoamine Oxidase Inhibitors. Part II. Treatment Correlates and Clinical Management. Journal of Clinical Psychopharmacology, 1985, 5, 2???9.	1.4	78
52	Social functioning in chronic depression: Effect of 6 weeks of antidepressant treatment. Psychiatry Research, 1988, 25, 213-222.	3.3	77
53	Substance use disorder comorbidity in major depressive disorder: an exploratory analysis of the Sequenced Treatment Alternatives to Relieve Depression cohort. Comprehensive Psychiatry, 2005, 46, 81-89.	3.1	75
54	Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug and Alcohol Dependence, 2010, 107, 161-170.	3.2	71

#	Article	IF	Citations
55	Acceptability of Second-Step Treatments to Depressed Outpatients: A STAR*D Report. American Journal of Psychiatry, 2007, 164, 753-760.	7.2	68
56	Adverse Reactions to Monoamine Oxidase Inhibitors. Part I. A Comparative Study. Journal of Clinical Psychopharmacology, 1984, 4, 270???278.	1.4	67
57	Treatment of Maternal Depression in a Medication Clinical Trial and Its Effect on Children. American Journal of Psychiatry, 2015, 172, 450-459.	7.2	62
58	Neurocognitive predictors of antidepressant clinical response. Journal of Affective Disorders, 2014, 166, 108-114.	4.1	61
59	Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. Neuropsychopharmacology, 2018, 43, 2221-2230.	5.4	61
60	Pattern recognition of magnetic resonance imaging-based gray matter volume measurements classifies bipolar disorder and major depressive disorder. Journal of Affective Disorders, 2018, 227, 498-505.	4.1	60
61	Association of Mu-Opioid Receptor Variants and Response to Citalopram Treatment in Major Depressive Disorder. American Journal of Psychiatry, 2010, 167, 565-573.	7.2	58
62	Predictors of Relapse During Fluoxetine Continuation or Maintenance Treatment of Major Depression. Journal of Clinical Psychiatry, 2000, 61, 518-524.	2.2	56
63	Predictive Value of Symptoms of Atypical Depression. Journal of Clinical Psychopharmacology, 1992, 12, 197???202.	1.4	54
64	A genome-wide association study of a sustained pattern of antidepressant response. Journal of Psychiatric Research, 2013, 47, 1157-1165.	3.1	52
65	A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives. International Journal of Eating Disorders, 1994, 15, 1-9.	4.0	51
66	Baseline characteristics of 10-day placebo washout responders in antidepressant trials. Psychiatry Research, 1987, 21, 9-22.	3.3	50
67	Dr. Quitkin and Associates Reply. American Journal of Psychiatry, 1988, 145, 1322-b-1322.	7.2	50
68	Do atypical features affect outcome in depressed outpatients treated with citalopram?. International Journal of Neuropsychopharmacology, 2010, 13, 15.	2.1	50
69	Defining the boundaries of atypical depression: Evidence from the HPA axis supports course of illness distinctions. Journal of Affective Disorders, 2005, 86, 161-167.	4.1	49
70	Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial. Biological Psychiatry, 2019, 85, 872-880.	1.3	48
71	Gepirone Treatment of Atypical Depression. Journal of Clinical Psychopharmacology, 1994, 14, 347???352.	1.4	47
72	Demonstrating testâ€retest reliability of electrophysiological measures for healthy adults in a multisite study of biomarkers of antidepressant treatment response. Psychophysiology, 2017, 54, 34-50.	2.4	46

#	Article	IF	Citations
73	Do Age of Onset and Course of Illness Predict Different Treatment Outcome among DSM IV Depressive Disorders with Atypical Features?. Neuropsychopharmacology, 2002, 26, 237-245.	5.4	44
74	DSM-IV Depression with Atypical Features: Is It Valid?. Neuropsychopharmacology, 2009, 34, 2625-2632.	5.4	44
75	The association between antidepressant treatment and brain connectivity in two double-blind, placebo-controlled clinical trials: a treatment mechanism study. Lancet Psychiatry,the, 2019, 6, 667-674.	7.4	44
76	A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER. Depression and Anxiety, 2016, 33, 56-65.	4.1	43
77	Sleep of atypical depressives. Journal of Affective Disorders, 1985, 8, 61-67.	4.1	42
78	Dichotic Listening Tests of Functional Brain Asymmetry Predict Response to Fluoxetine in Depressed Women and Men. Neuropsychopharmacology, 2004, 29, 1752-1761.	5.4	42
79	Comparison of the effects of fluoxetine, imipramine and placebo on personality in atypical depression. Journal of Affective Disorders, 2002, 71, 113-120.	4.1	41
80	Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Psychiatry Research, 2008, 161, 116-120.	3.3	40
81	Modafinil Treatment for Fatigue in HIV/AIDS. Journal of Clinical Psychiatry, 2010, 71, 707-715.	2.2	40
82	Atypical depression: Enhanced right hemispheric dominance for perceiving emotional chimeric faces.. Journal of Abnormal Psychology, 2002, 111, 446-454.	1.9	39
83	A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. Psychotherapy and Psychosomatics, 2018, 87, 285-295.	8.8	39
84	Left Hemisphere Dysfunction During Verbal Dichotic Listening Tests in Patients Who Have Social Phobia With or Without Comorbid Depressive Disorder. American Journal of Psychiatry, 2004, 161, 72-78.	7.2	35
85	Development and evaluation of a multimodal marker of major depressive disorder. Human Brain Mapping, 2018, 39, 4420-4439.	3.6	35
86	Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. International Clinical Psychopharmacology, 2010, 25, 214-217.	1.7	34
87	Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 145-150.	3.2	34
88	Remission Rates With 3 Consecutive Antidepressant Trials. Journal of Clinical Psychiatry, 2005, 66, 670-676.	2.2	34
89	Abnormal functional brain asymmetry in depression: Evidence of biologic commonality between major depression and dysthymia. Psychiatry Research, 2012, 196, 250-254.	3.3	33
90	Combination antidepressant therapy for major depressive disorder: Speed and probability of remission. Journal of Psychiatric Research, 2014, 52, 7-14.	3.1	33

#	Article	IF	Citations
91	Placebo run-in period in studies of depressive disorders. British Journal of Psychiatry, 1998, 173, 242-248.	2.8	32
92	Monoamine Oxidase Inhibitors in Bipolar Endogenous Depressives. Journal of Clinical Psychopharmacology, 1981, 1, 70-74.	1.4	31
93	Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance ImagingÂStudy. Biological Psychiatry, 2018, 84, 563-573.	1.3	31
94	Identifying the Common Genetic Basis of Antidepressant Response. Biological Psychiatry Global Open Science, 2022, 2, 115-126.	2.2	31
95	Predictors of Therapeutic Response to Treatments for Depression: A Review of Electrophysiologic and Dichotic Listening Studies. CNS Spectrums, 1999, 4, 30-36.	1.2	30
96	EEG Hemispheric Asymmetries during Cognitive Tasks in Depressed Patients with High versus Low Trait Anxiety. Clinical EEG and Neuroscience, 2010, 41, 196-202.	1.7	30
97	Effects of Race and Ethnicity on Depression Treatment Outcomes: The CO-MED Trial. Psychiatric Services, 2011, 62, 1167-1179.	2.0	30
98	A comparison of structural connectivity in anxious depression versus non-anxious depression. Journal of Psychiatric Research, 2017, 89, 38-47.	3.1	30
99	Switching to Reboxetine: An Efficacy and Safety Study in Patients With Major Depressive Disorder Unresponsive to Fluoxetine. Journal of Clinical Psychopharmacology, 2003, 23, 365-369.	1.4	29
100	Brain regulation of emotional conflict predicts antidepressant treatment response for depression. Nature Human Behaviour, 2019, 3, 1319-1331.	12.0	29
101	Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals. Molecular Psychiatry, 2020, 25, 1526-1536.	7.9	29
102	Efficacy of desipramine in endogenomorphically depressed patients. Journal of Affective Disorders, 1980, 2, 165-176.	4.1	28
103	Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study. Magnetic Resonance Imaging, 2018, 45, 26-33.	1.8	28
104	Discovery and replication of cerebral bloodÂflow differences in major depressive disorder. Molecular Psychiatry, 2020, 25, 1500-1510.	7.9	28
105	THE MANAGEMENT OF TREATMENT RESISTANCE IN DEPRESSED PATIENTS WITH SUBSTANCE USE DISORDERS. Psychiatric Clinics of North America, 1996, 19, 311-327.	1.3	27
106	Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly Associated With Depression. Biological Psychiatry, 2020, 87, 419-430.	1.3	27
107	Response to Zhang et al., (2005) Loss-of-Function Mutation in Tryptophan Hydroxylase-2 Identified in Unipolar Major Depression. Neuron 45, 11â€“16. Neuron, 2005, 48, 702-703.	8.1	26
108	Can People With Nonsevere Major Depression Benefit From Antidepressant Medication?. Journal of Clinical Psychiatry, 2012, 73, 518-525.	2.2	26

#	Article	IF	Citations
109	Resting EEG Measures of Brain Arousal in a Multisite Study of Major Depression. Clinical EEG and Neuroscience, 2019, 50, 3-12.	1.7	25
110	Study duration in antidepressant research: Advantages of a 12-week trial. Journal of Psychiatric Research, 1986, 20, 211-216.	3.1	24
111	Lactate provocation of panic attacks in depressed outpatients. Psychiatry Research, 1988, 25, 41-47.	3.3	23
112	Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse. Biological Psychiatry, 2020, 88, 657-667.	1.3	23
113	Statistical analysis plan for stage 1 EMBARC (Establishing Moderators and Biosignatures of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T f 5 6, 22-30.	1.1	22
114	Placebo-Controlled Study of Mianserin in Depressed Outpatients. Neuropsychobiology, 1985, 14, 128-132.	1.9	21
115	Do age of onset and course of illness define biologically distinct groups within atypical depression?. Journal of Abnormal Psychology, 2003, 112, 253-262.	1.9	21
116	A Reappraisal of Atypical Depression. American Journal of Psychiatry, 2003, 160, 798-b-800.	7.2	21
117	Accounting for Dynamic Fluctuations across Time when Examining fMRI Test-Retest Reliability: Analysis of a Reward Paradigm in the EMBARC Study. PLoS ONE, 2015, 10, e0126326.	2.5	20
118	A Randomized Controlled Trial of Duloxetine Versus Placebo in the Treatment of Nonmajor Chronic Depression. Journal of Clinical Psychiatry, 2012, 73, 984-991.	2.2	20
119	A comparative study of the pituitary TSH response to thyrotropin in outpatient depressives. Psychiatry Research, 1984, 12, 185-193.	3.3	19
120	Follow-up of Patients Who Improved During Placebo Washout. Journal of Clinical Psychopharmacology, 1986, 6, 274???278.	1.4	19
121	Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial. EClinicalMedicine, 2019, 10, 32-41.	7.1	19
122	CURRENT CONCEPTS IN THE TREATMENT OF DEPRESSION IN ALCOHOL-DEPENDENT PATIENTS. Psychiatric Clinics of North America, 2000, 23, 695-711.	1.3	18
123	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. Focus (American Psychiatric Publishing), 2008, 6, 128-142.	0.8	17
124	Neuroticism and Individual Differences in Neural Function in Unmedicated Major Depression: Findings From the EMBARC Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 138-148.	1.5	17
125	Cortical thickness is not associated with current depression in a clinical treatment study. Human Brain Mapping, 2017, 38, 4370-4385.	3.6	17
126	Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control. Journal of Affective Disorders, 2019, 245, 1070-1078.	4.1	17

#	Article	IF	Citations
127	Bromocriptine Treatment of Relapses Seen During Selective Serotonin Re-uptake Inhibitor Treatment of Depression. Journal of Clinical Psychopharmacology, 1995, 15, 289-291.	1.4	17
128	Atypical depression: Enhanced right hemispheric dominance for perceiving emotional chimeric faces.. Journal of Abnormal Psychology, 2002, 111, 446-454.	1.9	17
129	Association of Whole-Genome and NETRIN1 Signaling Pathwayâ€"Derived Polygenic Risk Scores for Major Depressive Disorder and White Matter Microstructure in the UK Biobank. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 91-100.	1.5	16
130	Deficits of white matter axial diffusivity in bipolar disorder relative to major depressive disorder: No relationship to cerebral perfusion or body mass index. Bipolar Disorders, 2020, 22, 296-302.	1.9	16
131	Do tricyclic responders have different brain laterality?. Journal of Abnormal Psychology, 1999, 108, 707-710.	1.9	14
132	The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. Journal of Psychopharmacology, 2019, 33, 185-193.	4.0	14
133	Variants in PDE11A and PDE1A are not associated with citalopram response. Molecular Psychiatry, 2007, 12, 1061-1063.	7.9	13
134	Predicting therapeutic response to secondary treatment with bupropion: Dichotic listening tests of functional brain asymmetry. Psychiatry Research, 2007, 153, 137-143.	3.3	12
135	Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Annals of General Psychiatry, 2010, 9, 10.	2.7	12
136	White matter tract integrity is associated with antidepressant response to lurasidone in bipolar depression. Bipolar Disorders, 2017, 19, 444-449.	1.9	12
137	Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study. Journal of Psychiatric Research, 2018, 102, 207-215.	3.1	12
138	Examining raphe-amygdala structural connectivity as a biological predictor of SSRI response. Journal of Affective Disorders, 2019, 256, 8-16.	4.1	12
139	Dynamic Resting-State Network Biomarkers of Antidepressant Treatment Response. Biological Psychiatry, 2022, 92, 533-542.	1.3	12
140	Mianserin versus Amitriptyline for Depression: A Double-Blind 6-Week Trial. Neuropsychobiology, 1984, 12, 224-228.	1.9	11
141	Predictors of Antidepressant Response in Depressed Alcoholic Patients. American Journal on Addictions, 1996, 5, 308-312.	1.4	11
142	Does Dual Antidepressant Therapy as Initial Treatment Hasten and Increase Remission from Depression?. Journal of Psychiatric Practice, 2009, 15, 337-345.	0.7	11
143	Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial. Biological Psychiatry, 2022, 91, 550-560.	1.3	9
144	Cortisol response to dextroamphetamine stimulation in depressed outpatients. Psychiatry Research, 1984, 12, 195-206.	3.3	8

#	Article	IF	Citations
145	Do social functioning and symptoms improve with continuation antidepressant treatment of persistent depressive disorder? An observational study. Journal of Affective Disorders, 2017, 210, 258-264.	4.1	8
146	Effects of imipramine and phenelzine on plasma PEA levels. Psychiatry Research, 1988, 26, 239.	3.3	6
147	Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial. Psychological Medicine, 2022, 52, 2441-2449.	4.5	6
148	Lateralization for speech predicts therapeutic response to cognitive behavioral therapy for depression. Psychiatry Research, 2015, 228, 606-611.	3.3	5
149	Desvenlafaxine vs. placebo in the treatment of persistent depressive disorder. Journal of Affective Disorders, 2019, 245, 403-411.	4.1	5
150	The Use of Monoamine Oxidase Inhibitors for Treating Atypical Depression. Psychiatric Annals, 2001, 31, 371-375.	0.1	5
151	Bromocriptine Treatment for Cocaine Addiction. American Journal on Addictions, 1993, 2, 169-172.	1.4	4
152	Is duloxetine effective treatment for depression with atypical features?. International Clinical Psychopharmacology, 2008, 23, 333-336.	1.7	4
153	Electrophysiological predictors of clinical response to antidepressants. , 2013, , 380-393.		4
154	Dysthymia and chronic depression. , 2013, , 20-36.		4
155	Resting State MRI Amplitude of Low Frequency Fluctuations Associated With Suicidal Ideation in Bipolar Depression. Journal of Clinical Psychiatry, 2022, 83, .	2.2	4
156	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial. Journal of Psychiatric Research, 2022, 149, 243-251.	3.1	4
157	Cilobamine in the treatment of atypical depression. Human Psychopharmacology, 1988, 3, 201-205.	1.5	3
158	Co-occurring anxiety and depression: concepts, significance, and treatment implications. , 0, , 90-102.		3
159	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. Focus (American Psychiatric Publishing), 2008, 6, 104-119.	0.8	2
160	Serotonin-norepinephrine reuptake inhibitor antidepressant effects on regional connectivity of the thalamus in persistent depressive disorder: evidence from two randomized, double-blind, placebo-controlled clinical trials. Brain Communications, 2022, 4, fcac100.	3.3	2
161	Does Imipramine Worsen Atypical Depression?. Journal of Clinical Psychopharmacology, 1991, 11, 270???271.	1.4	1
162	Pharmacological Management of Treatment-Resistant Unipolar Depression. , 2015, , 2311-2330.		1

#	Article	IF	Citations
163	Treatment of Maternal Depression in a Medication Clinical Trial and Its Effect on Children. Focus (American Psychiatric Publishing), 2016, 14, 103-112.	0.8	1
164	Treatment of melancholia with tranylcypromine. Journal of Clinical Psychopharmacology, 1984, 4, 167.	1.4	0
165	Treatment of Depression in Alcohol-Dependent Patients. Disease Management and Health Outcomes, 1997, 2, 22-33.	0.4	0
166	Depression in the context of alcoholism and other substance-use disorders. , 0, , 234-244.		0
167	Atypical depression. , 0, , 59-74.		0
168	Complementary and alternative treatments for mood disorders. , 0, , 245-257.		0
169	Pharmacogenetics and mood disorders. , 0, , 368-379.		0
170	Classifying Depression. American Journal of Psychiatry, 2001, 158, 1332-a-1333.	7.2	0
171	Pharmacologic Management of Treatment-Resistant Unipolar Depression. , 0, , 2372-2389.		0